Transcriptional Signature of Macrophages in SSc
SSc 中巨噬细胞的转录特征
基本信息
- 批准号:10005890
- 负责人:
- 金额:$ 17.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2021-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectBilateralBiologyBiopsyCase Fatality RatesCellceptCellsClinicalClinical ResearchCollaborationsComplexCross-Sectional StudiesDataDermalDevelopmentDiseaseDouble-Blind MethodDrug TargetingEnrollmentFibrosisFlow CytometryForearmFrequenciesFutureGene Expression ProfileGene Expression ProfilingGenetic TranscriptionGoalsGoldGrantImmunohistochemistryImmunomodulatorsInflammationInflammatoryInjuryKnowledgeLightLungLung diseasesLymphocyteMeta-AnalysisMolecularMorbidity - disease rateMycophenolateNaturePathogenesisPathway interactionsPatientsPhenotypePlayPopulationProtocols documentationPublicationsRandomizedResearch PersonnelResolutionRheumatismRoleSclerodermaSeriesSkinSkin TissueSystemic SclerodermaTechnologyTestingTherapeuticTherapeutic InterventionTimeTrichrome stainWorkbasebiomedical referral centercell typecellular targetingcohorteffective therapyexperimental studyhigh rewardhigh riskhistological studiesmacrophagemonocytemortalitymycophenolate mofetilnew therapeutic targetnext generation sequencingnovelnovel strategiesperipheral bloodprogramsprospectiverecruitresponders and non-respondersresponseskin disorderskin fibrosistertiary caretranscriptometranscriptome sequencingtranscriptomicstreatment responderstreatment response
项目摘要
SSc is associated with significant morbidity and mortality and available therapeutic options have only limited
efficacy. Macrophages are thought to play a major role in the pathogenesis of SSc dermal disease because
they can alter their phenotype between pro-inflammation and pro-fibrosis/injury resolution. Additionally, recent
advances in high-throughput molecular technologies that analyzed whole tissue skin biopsies from SSc
patients suggest that macrophages are important cellular targets in SSc, but the precise role macrophages
play in SSc dermal fibrosis is unknown. We will take advantage of cutting edge technology that will allow for
isolation of macrophages from skin biopsies using multi-parameter flow cytometry and analyze their gene
expression profile using RNAseq. Skin biopsies will be obtained from healthy control subjects and from
patients with SSc to identify the SSc-specific dermal macrophage signature. We will also obtain skin biopsies
from SSc patients before and post mycophenolate mofetil (MMF) treatment and compare signatures between
treatment responders and non-responders compared to untreated patients. These studies are timely because
recent data from the first randomized double-blinded clinical study suggest that MMF is a useful agent for SSc
skin disease. We hypothesize that macrophages are a potential treatment target for patients with SSc dermal
disease, and that the new knowledge gained from the proposed studies will shed light upon the role that
macrophages play in dermal fibrosis in SSc. These studies, while high-risk, will generate high reward
information that has the potential be to paradigm shifting and is ideal for the R21 grant mechanism.
!
SSc与显著的发病率和死亡率相关,可用的治疗选择仅有限
功效巨噬细胞被认为在SSc皮肤病的发病机制中发挥重要作用,
它们可以在促炎症和促纤维化/损伤消退之间改变其表型。此外,最近
高通量分子技术的进展,分析了SSc的全组织皮肤活检,
患者提示巨噬细胞是SSc中重要的细胞靶点,但巨噬细胞的确切作用
在SSc真皮纤维化中的作用尚不清楚。我们将利用尖端技术,
多参数流式细胞术分离皮肤巨噬细胞及其基因分析
使用RNAseq的表达谱。皮肤活组织检查将从健康对照受试者和从健康对照受试者获得。
与SSc患者,以确定SSc特异性真皮巨噬细胞签名。我们还将获得皮肤活检
从SSc患者之前和之后霉酚酸酯(MMF)治疗,并比较签名之间
与未治疗的患者相比,治疗应答者和无应答者。这些研究是及时的,因为
来自第一个随机双盲临床研究的最新数据表明,MMF是治疗SSc的有效药物
皮肤病我们假设巨噬细胞是SSc皮肤病患者的潜在治疗靶点,
疾病,从拟议的研究中获得的新知识将阐明
巨噬细胞在SSc的真皮纤维化中起作用。这些研究虽然风险很高,但回报也很高
信息有可能是范式转移,是理想的R21赠款机制。
!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Harris R Perlman其他文献
Harris R Perlman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Harris R Perlman', 18)}}的其他基金
Macrophage Heterogeneity in Rheumatoid Arthritis
类风湿关节炎中的巨噬细胞异质性
- 批准号:
10392246 - 财政年份:2022
- 资助金额:
$ 17.38万 - 项目类别:
Macrophage Heterogeneity in Rheumatoid Arthritis
类风湿关节炎中的巨噬细胞异质性
- 批准号:
10609468 - 财政年份:2022
- 资助金额:
$ 17.38万 - 项目类别:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
用于预测治疗效果的滑膜巨噬细胞转录特征
- 批准号:
10679089 - 财政年份:2019
- 资助金额:
$ 17.38万 - 项目类别:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
用于预测治疗效果的滑膜巨噬细胞转录特征
- 批准号:
10460247 - 财政年份:2019
- 资助金额:
$ 17.38万 - 项目类别:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
用于预测治疗效果的滑膜巨噬细胞转录特征
- 批准号:
9766023 - 财政年份:2019
- 资助金额:
$ 17.38万 - 项目类别:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
用于预测治疗效果的滑膜巨噬细胞转录特征
- 批准号:
10020786 - 财政年份:2019
- 资助金额:
$ 17.38万 - 项目类别:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
用于预测治疗效果的滑膜巨噬细胞转录特征
- 批准号:
10242125 - 财政年份:2019
- 资助金额:
$ 17.38万 - 项目类别:
RhEumatoid Arthritis SynOvial tissue Network (REASON)
类风湿性关节炎滑膜组织网络 (REASON)
- 批准号:
9130014 - 财政年份:2014
- 资助金额:
$ 17.38万 - 项目类别:
RhEumatoid Arthritis SynOvial tissue Network (REASON)
类风湿性关节炎滑膜组织网络 (REASON)
- 批准号:
9130011 - 财政年份:2014
- 资助金额:
$ 17.38万 - 项目类别:
相似国自然基金
High-precision force-reflected bilateral teleoperation of multi-DOF hydraulic robotic manipulators
- 批准号:52111530069
- 批准年份:2021
- 资助金额:10 万元
- 项目类别:国际(地区)合作与交流项目
相似海外基金
A Study of Policy Convergence between Multilateral and Bilateral Donors' Support for Community Participation in Education in Cambodia
柬埔寨社区参与教育的多边和双边捐助者支持政策趋同研究
- 批准号:
24K05750 - 财政年份:2024
- 资助金额:
$ 17.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bilateral ESRC/FNR: Training Executives to Enhance Employee Engagement in Government: Field Experimental Evidence from Luxembourg
双边 ESRC/FNR:培训高管以提高员工在政府中的参与度:来自卢森堡的现场实验证据
- 批准号:
ES/W010380/1 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Research Grant
Design and testing of a novel circumesophageal cuff for chronic bilateral subdiaphragmatic vagal nerve stimulation (sVNS)
用于慢性双侧膈下迷走神经刺激(sVNS)的新型环食管套囊的设计和测试
- 批准号:
10702126 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Optimizing bilateral and single-sided-deafness cochlear implants for functioning in complex auditory environments
优化双侧和单侧耳聋人工耳蜗植入物以在复杂的听觉环境中发挥作用
- 批准号:
10654316 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Investigating subthreshold vestibular stimulation as a strategy for rehabilitation in individuals with bilateral vestibular hypofunction
研究阈下前庭刺激作为双侧前庭功能减退患者的康复策略
- 批准号:
10571440 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Conference: NSF/UKRI Bilateral Workshop on Quantum Information Science in Chemistry
会议:NSF/UKRI 化学中量子信息科学双边研讨会
- 批准号:
2403812 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Standard Grant
Factors for bilateral capital inflows into emerging market economies from advanced economies
发达经济体双边资本流入新兴市场经济体的因素
- 批准号:
23K01461 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Shift from Unilateral to Bilateral Sensory-Motor Connectivity in Chronic Hemiparetic Stroke
慢性偏瘫中风从单侧感觉运动连接转向双侧感觉运动连接
- 批准号:
10991213 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Bilateral ESRC/FNR: Banking on Europe
双边 ESRC/FNR:欧洲银行业
- 批准号:
ES/W000733/2 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Research Grant
Mutual Teaching System of Motion by Robot and Human Based on Force-Based 2-channel Bilateral Control
基于力基二通道双边控制的机器人与人运动互示系统
- 批准号:
23K03767 - 财政年份:2023
- 资助金额:
$ 17.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




